2026

（原著論文）

• Ampicillin/ceftriaxone vs. β-lactam/aminoglycoside combination therapy for Enterococcus faecalis infective endocarditis: a systematic review and meta-analysis.
  Sugimoto Y, Sasaki R, Tominaga M, Hirai R, Mihara T, Shimamura R, Yoshikawa M, Ikegami S, Shimada S, Tsubouchi A, Okamoto Y, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K.
  Eur J Clin Microbiol Infect Dis. in press Abstract
• Comparative Efficacy and Safety of 15-Valent and 13-Valent Pneumococcal Conjugate Vaccines Alone and in Combination with the 23-Valent Polysaccharide Vaccine: A Systematic Review and Meta-analysis.
  Matsumoto Y, Mihara T, Okamoto Y, Tsubouchi A, Ikegami S, Takahashi M, Nakabayashi K, Nishimoto N, Mizukami Y, Muraishi T, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K.
  Biol Pharm Bull. 2026; 49(7): 1073-1086. Abstract
• Three fluoroquinolones with different epithelial lining fluid penetration in a murine lung infection model: an experimental site-specific PK/PD study.
  Hosoi A, Duan S, Shimada S, Suzuki K, Mizukami Y, Shintani R, Takahashi M, Satake N, Muraishi T, Okamoto Y, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K.
  Antimicrob Agents Chemother. 2026; 70(8): e0037526. Abstract
• Age and body weight-adjusted infusion rate (mg/kg/h) as risk factors for vancomycin infusion reaction in patients receiving perioperative antimicrobial prophylaxis: a retrospective cohort study.
  Iketani O, Uno S, Shinjoh M, Takemura R, Fukuda S, Seyama S, Kimura M, Ishikawa H, Hayakawa T, Uwamino Y, Namkoong H, Yoshifuji A, Obara H, Takano Y, Enoki Y, Taguchi K, Sato Y, Matsumoto K, Hasegawa N.
  JAC Antimicrob Resist. 2026; 8(3): dlag084. Abstract
• PCV13/PPSV23 Co-vaccination versus PPSV23 Monotherapy for the Prevention of Pneumococcal Infections: A Systematic Review and Meta-analysis.
  Matsumoto Y, Mihara T, Okamoto Y, Tsubouchi A, Ikegami S, Takahashi M, Nakabayashi K, Nishimoto N, Mizukami Y, Muraishi T, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K.
  Biol Pharm Bull. 2026; 49(4): 666-682. Abstract
• Establishing an assay to evaluate d-amino acid oxidase enzyme kinetics and inhibition using WST-8 redox dye.
  Miyake K, Enoki Y, Nakazawa Y, Taguchi K, Matsumoto K.
  FEBS Open Bio. 2026; 16(9): 1645-1656. Abstract
• Impact of Chronic Kidney Disease on the Onset of Sepsis: A Systematic Review.
  Osa S, Enoki Y, Endo A, Kumamoto K, Kobayashi K, Komiya C, Satake N, Kawakami J, Yagi T, Taguchi K, Matsumoto K.
  Biol Pharm Bull. 2026; 49(1): 99-107. Abstract
• Secreted protein acidic and rich in cysteine-guided biomimetic delivery of nano-antioxidants reverses muscle atrophy in a mouse model of sarcopenia.
  Kanazawa G, Maeda H, Yasuda K, Noguchi I, Nishinoiri A, Taguchi K, Imoto S, Tsukigawa K, Yamasaki K, Sakuragi M, Ishima Y, Matsushita S, Nakamura T, Saruwatari J, Otagiri M, Watanabe H, Maruyama T.
  J Control Release. 2026; 391: 114567. Abstract
• Stepwise dual N-terminal modification of proteins via nickel(II)-mediated aldol and Pictet-Spengler reactions.
  Hanaya K, Morimi Y, Usui S, Taguchi K, Wada Y, Kawano M, Higashibayashi S, Sugai T.
  Tetrahedron Chem. 2026; 17: 100154. Abstract
• Application of epithelial lining fluid drug concentrations to MIC_i-Based PK/PD modeling of cefepime/nacubactam in a murine model of CPE pneumonia.
  Mizukami Y, Takahashi M, Suzuki K, Duan S, Ikegami S, Muraishi T, Satake N, Okamoto Y, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K.
  J Infect Chemother. 2026; 32(1): 102889. Abstract
• Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system.
  Takada K, Enoki Y, Samura M, Igarashi Y, Taguchi K, Tanikawa K, Matsumoto K.
  Expert Opin Drug Saf. 2026; 25(9): 1731-1737. Abstract

（総説論文）

• When Red Blood Cells Meet Carbon Monoxide: Yin and Yang in Medicines and Pharmaceuticals.
  Nagasaki T, Chuang VTG, Otagiri M, Taguchi K.
  Pharmaceuticals (Basel). 2026; 19(4): 634. Abstract